Major Milestone: Akero Therapeutics Launches Phase 3 Trial for Efruxifermin in Compensated Cirrhosis Patients
Tuesday, 11 June 2024, 08:12
Akero Therapeutics Initiates Phase 3 SYNCHRONY Outcomes Trial
Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
Akero Therapeutics has announced the initiation of the Phase 3 SYNCHRONY Outcomes Trial to evaluate the efficacy of Efruxifermin in patients with compensated cirrhosis caused by MASH.
- Phase 3 trial marks a significant advancement in the treatment of compensated cirrhosis.
- Efruxifermin shows promise for potential therapeutic breakthroughs in MASH patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.